-
Journal of the Formosan Medical... Jun 2024
PubMed: 38945738
DOI: 10.1016/j.jfma.2024.06.025 -
Journal of Thrombosis and Haemostasis :... Jul 2024
"Finding a common definition of heparin resistance in adult cardiac surgery: Communication from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis": reply.
Topics: Humans; Heparin; Cardiac Surgical Procedures; Thrombosis; Anticoagulants; Drug Resistance; Hemostasis; Critical Care; Perioperative Care; Adult
PubMed: 38945670
DOI: 10.1016/j.jtha.2024.04.014 -
Journal of Thrombosis and Haemostasis :... Jul 2024
"Finding a common definition of heparin resistance in adult cardiac surgery: Communication from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis": comment from Mansour et al.
Topics: Humans; Heparin; Cardiac Surgical Procedures; Thrombosis; Anticoagulants; Drug Resistance; Adult; Hemostasis; Perioperative Care; Critical Care
PubMed: 38945669
DOI: 10.1016/j.jtha.2024.03.026 -
Journal of Thrombosis and Haemostasis :... Jul 2024
"Finding a common definition of heparin resistance in adult cardiac surgery: Communication from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis": comment from Boissier et al.
Topics: Humans; Heparin; Cardiac Surgical Procedures; Thrombosis; Anticoagulants; Drug Resistance; Hemostasis; Adult; Critical Care; Perioperative Care
PubMed: 38945668
DOI: 10.1016/j.jtha.2024.03.025 -
Journal of Thrombosis and Haemostasis :... Jul 2024
Topics: Humans; Vitamin K; Perioperative Care; Anticoagulants; Blood Coagulation
PubMed: 38945667
DOI: 10.1016/j.jtha.2024.04.012 -
Food Research International (Ottawa,... Aug 2024To improve the color stability of anthocyanins (ACNs) in blueberry fermented beverage, the intermolecular copigmentation between ACNs and 3 different phenolic compounds,...
To improve the color stability of anthocyanins (ACNs) in blueberry fermented beverage, the intermolecular copigmentation between ACNs and 3 different phenolic compounds, including (-)-epigallocatechin gallate (EGCG), ferulic acid (FA), and gallic acid (GA) as copigments, was compared in the model and the real blueberry fermented beverage, respectively. The copigmented ACNs by EGCG presented a high absorbance (0.34 a.u.) and redness (27.09 ± 0.17) in the model blueberry fermented beverage. The copigmentation by the participation of the 3 different phenolic compounds showed all a spontaneous exothermic reaction, and the Gibbs free energy (ΔG°) of the system was lowest (-5.90 kJ/mol) using EGCG as copigment. Furthermore, the molecular docking model verified that binary complexes formed between ACNs and copigments by hydrogen bonds and π-π stacking. There was a high absorbance (1.02 a.u.), percentage polymeric color (PC%, 68.3 %), and good color saturation (C*ab, 43.28) in the real blueberry fermented beverage aged for 90 days, and more malvidin-3-O-glucoside had been preserved in the wine using EGCG as copigment. This finding may guide future industrial production of blueberry fermented beverage with improved color.
Topics: Anthocyanins; Blueberry Plants; Fermentation; Coumaric Acids; Molecular Docking Simulation; Gallic Acid; Phenols; Color; Catechin; Fruit and Vegetable Juices; Fruit
PubMed: 38945622
DOI: 10.1016/j.foodres.2024.114632 -
Revista Portuguesa de Cardiologia :... Jun 2024Oral anticoagulation (OAC) with non-vitamin K antagonist oral anticoagulants (NOACs) after surgical mitral valve repair (MVR) or bioprosthetic valve replacement (BVR) in...
INTRODUCTION AND OBJECTIVES
Oral anticoagulation (OAC) with non-vitamin K antagonist oral anticoagulants (NOACs) after surgical mitral valve repair (MVR) or bioprosthetic valve replacement (BVR) in mitral position remains a controversial topic among the cardiovascular community, in particular in the early postoperative period. This study aimed to evaluate the efficacy and safety of NOACs in the first three months after MVR or mitral BVR compared to vitamin K antagonists (VKAs).
METHODS
This was a single-center retrospective study with prospectively collected peri-intervention outcomes between 2020 and 2021. Records were retrieved and all participants were contacted by telephone. Patients were divided into groups according to OAC strategy. The primary outcome was a composite of death, rehospitalization, myocardial infarction, stroke or transient ischemic attack, systemic embolism, mitral thrombosis, or bleeding during the first three months after surgery.
RESULTS
A total of 148 patients were enrolled, with a mean age of 65.5±12.2 years, 56.8% male. On discharge, 98 (66.2%) patients were on VKAs and 50 (33.8%) were on DOACs for at least three months. The primary outcome occurred in 22 (22.4%) patients in the VKA group and in three (6%) in the NOAC group (p=0.012), mainly driven by more bleeding events in the former. Independent predictors of the primary outcome were smoking (p=0.028) and OAC with VKAs at discharge, the latter predicting three times more events (p=0.046, OR 3.72, 95% CI 1.02-13.5).
CONCLUSIONS
NOACs were associated with fewer events, supporting their efficacy and safety during the first three months after surgical MVR or mitral BVR.
PubMed: 38945474
DOI: 10.1016/j.repc.2024.02.013 -
Journal of Vascular Surgery. Venous and... Jun 2024We evaluated the impact of completion intraoperative venography on clinical outcomes for axillosubclavian vein (AxSCV) thrombosis due to venous thoracic outlet syndrome...
INTRODUCTION
We evaluated the impact of completion intraoperative venography on clinical outcomes for axillosubclavian vein (AxSCV) thrombosis due to venous thoracic outlet syndrome (vTOS).
METHODS
We performed a retrospective, single-center review of all patients with vTOS treated with First Rib Resection and intraoperative venography from 2011 - 2023. We reviewed intraoperative venographic films to classify findings, collected demographics, clinical and perioperative variables, and clinical outcomes. Primary endpoints were symptomatic relief and primary patency at 3 months and 1 year. Secondary endpoints were time free from symptoms, reintervention rate, perioperative complications, and mortality.
RESULTS
Fifty-one AxSCVs (49 patients, mean age of 31.3 ± 12.6, 52.9% female) were treated for vTOS with first rib resection and external venolysis followed by completion intraoperative venography with a mean follow up of 15.5 ± 13.5 months. Prior to FRR, 32 underwent catheter-directed thrombolysis (62.7%). Completion intraoperative venography identified 16 patients with No Stenosis (Group 1, 31.3%), 17 with No Stenosis after Angioplasty (Group 2, 33.3%), 10 with Residual Stenosis after Angioplasty (Group 3, 19.7%), and 8 with Complete Occlusion (Group 4, 15.7%). The overall symptomatic relief was 44 of 51 (86.3%) and did not differ between venographic classifications (Group 1: 14 of 16, Group 2: 13 of 17, Group 3: 10 of 10, and Group 4: 7 of 8; Log-Rank Test, p = 0.5). The overall 3-month and 1-year primary patency was 42 of 43 (97.7%) and 32 of 33 (97.0%), respectively (Group 1: 16 of 16 and 9 of 9; Group 2: 16 of 17 and 12 of 13; Group 3: 10 of 10, 5 of 5; Group 4: primary patency not obtained). There was one asymptomatic re-thrombosis that resolved with anticoagulation, and three patients underwent reintervention with venous angioplasty for significant symptom recurrence an average 2.89 ± 1.7 months after FRR.
CONCLUSION
Our single-center retrospective study demonstrates that FRR with completion intraoperative venography has excellent symptomatic relief, short- and mid-term patency despite residual venous stenosis and complete occlusion. While completion intraoperative venographic classification did not correlate with adverse outcomes, this protocol yielded excellent results and provides important clinical data for postoperative management. Our results also support a conservative approach to AxSCV occlusion identified after FRR.
PubMed: 38945363
DOI: 10.1016/j.jvsv.2024.101936 -
Journal of Vascular Surgery. Venous and... Jun 2024AND OBJECTIVES: Large vein diameter is associated with higher recanalization rates after endovenous thermal ablation procedures of the great and small saphenous veins....
INTRODUCTION
AND OBJECTIVES: Large vein diameter is associated with higher recanalization rates after endovenous thermal ablation procedures of the great and small saphenous veins. However, relatively few studies have explored the relationship between vein diameter and recanalization rates after mechanochemical ablation (MOCA).
METHODS
We conducted a retrospective review of patients with chronic venous insufficiency who underwent MOCA of the great or small saphenous vein from 2017-2021 at a single hospital. Patients with no follow-up ultrasound were excluded. Patients were classified as having a large (≥ 1 cm) or small (< 1 cm) treated vein. The primary outcomes were 2-year recanalization and reintervention of the treated segment.
RESULTS
A total of 186 MOCA procedures during the study period were analyzed. There was no difference in age, gender, history of venous thromboembolic events, use of anticoagulation, obesity, or length of treated segment between cohorts. Patients with large veins were less likely to have stasis ulcers compared to those with small veins (3.2% vs 21.5%; p<.05 on Fisher exact test). Patients with large veins had a higher incidence of local post-operative local complications (24.2% vs 7.2%, p<.05 on Chi-squared test). A survival analysis with Cox proportional hazards showed no significant difference in recanalization rates with larger vein diameters. However, obesity was found to significantly correlate with recanalization.
CONCLUSIONS
Large vein diameter was not associated with higher recanalization rates following MOCA of the great and small saphenous veins. However, obesity was found to correlate with recanalization rates.
PubMed: 38945360
DOI: 10.1016/j.jvsv.2024.101935 -
Toxicon : Official Journal of the... Jun 2024The venoms of Australasian elapid snakes are known to possess coagulant activity, including some with strong procoagulant activity and others with anticoagulant...
The venoms of Australasian elapid snakes are known to possess coagulant activity, including some with strong procoagulant activity and others with anticoagulant activity, although the latter are less well known. This study investigates the anticoagulant activity of Australasian elapid snake venoms, and whether this activity is neutralised by commercial snake antivenom and varespladib (PLA inhibiting agent). Clotting assays were completed for 34 species of Australasian elapids. Antivenom neutralisation assays with tiger snake antivenom (TSAV) were performed on five species to determine if there was cross-neutralisation. Varespladib neutralisation assays were also completed for the same five species. All Pseudechis species venoms had anticoagulant activity, except P. porphyriacus, which was procoagulant. Pseudechis species venoms had similar anticoagulant potency ranging from the most potent P. colletti venom to the least potent P. butleri venom. The three Austrelaps (copperhead) species venoms were the next most potent anticoagulants. Six further snakes, Elapognathus coronatus, Acanthophis pyrrhus, A. antarcticus, Suta suta, Denisonia devisi and D. maculata, had weaker anticoagulant activity, except for D. maculata which had similar anticoagulant activity to Pseudechis species. Tiger Snake Antivenom (1200mU/mL) neutralised the anticoagulant effect of P. australis for concentrations up to 1 mg/mL. TSAV (1200mU/mL) also neutralised P. colletti, D. maculata, A. superbus and A. pyrrhus venoms at their EC, demonstrating cross neutralisation. Varespladib neutralised the anticoagulant effect of P. australis venom at 5μM and for venoms of P. colletti, D. maculata, A. superbus and A. pyrrhus. We found anticoagulant activity to be present in six genera of Australasian snakes at low concentrations, which can be completely neutralised by both antivenom and varespladib. Anticoagulant activity in Australian elapid venoms was associated with species possessing high PLA activity without procoagulant snake venom serine proteases.
PubMed: 38945217
DOI: 10.1016/j.toxicon.2024.107836